These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

697 related items for PubMed ID: 28915900

  • 1. A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II-IIIA non-small cell lung cancer: study protocol for a randomized controlled trial.
    Saka H, Kitagawa C, Ichinose Y, Takenoyama M, Ibata H, Kato T, Takami K, Yamashita M, Maeda T, Takeo S, Ueda H, Okabayashi K, Nagashima S, Oka T, Kouso H, Fukuyama S, Yoshimoto K, Shimokawa M, Saito AM, Ito S.
    Trials; 2017 Sep 15; 18(1):429. PubMed ID: 28915900
    [Abstract] [Full Text] [Related]

  • 2. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
    Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yan HH, Yang XN, Zhou Q, Wu YL, ADJUVANT investigators.
    Lancet Oncol; 2018 Jan 15; 19(1):139-148. PubMed ID: 29174310
    [Abstract] [Full Text] [Related]

  • 3. A randomized phase II study of S-1 monotherapy versus cisplatin with vinorelbine for completely resected stage II/IIIA non-small cell lung cancer: rationale and study protocol design for the LOGIK1702 study.
    Tsuchiya T, Matsumoto K, Miyazaki T, Doi R, Tokunaga S, Yamaguchi H, Tomoshige K, Watanabe H, Nagayasu T, Sugio K.
    BMC Cancer; 2021 Mar 08; 21(1):249. PubMed ID: 33685421
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Adjuvant vinorelbine and cisplatin after complete resection of stage II and III non-small cell lung cancer: long-term follow-up of our study of Japanese patients.
    Sonobe M, Hamaji M, Motoyama H, Menju T, Aoyama A, Chen-Yoshikawa TF, Sato T, Date H.
    Surg Today; 2018 Jul 08; 48(7):687-694. PubMed ID: 29502152
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Adjuvant chemotherapy with sequential cytokine-induced killer (CIK) cells in stage IB non-small cell lung cancer.
    Li DP, Li W, Feng J, Chen K, Tao M.
    Oncol Res; 2015 Jul 08; 22(2):67-74. PubMed ID: 25706393
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin.
    Chang WJ, Sun JM, Lee JY, Ahn JS, Ahn MJ, Park K.
    Lung Cancer; 2014 Apr 08; 84(1):51-5. PubMed ID: 24521819
    [Abstract] [Full Text] [Related]

  • 12. Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study).
    Kreuter M, Vansteenkiste J, Fischer JR, Eberhardt WE, Zabeck H, Kollmeier J, Serke M, Frickhofen N, Reck M, Engel-Riedel W, Neumann S, Thomeer M, Schumann C, De Leyn P, Graeter T, Stamatis G, Griesinger F, Thomas M, TREAT investigators.
    J Thorac Oncol; 2016 Jan 08; 11(1):85-93. PubMed ID: 26762743
    [Abstract] [Full Text] [Related]

  • 13. Adjuvant carboplatin-based chemotherapy in resected stage IIIA-N2 non-small cell lung cancer.
    Ou W, Sun HB, Ye X, Zhang BB, Yang H, Fang Q, Li P, Wang SY.
    J Thorac Oncol; 2010 Jul 08; 5(7):1033-41. PubMed ID: 20502361
    [Abstract] [Full Text] [Related]

  • 14. Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT).
    Tada H, Mitsudomi T, Misumi T, Sugio K, Tsuboi M, Okamoto I, Iwamoto Y, Sakakura N, Sugawara S, Atagi S, Takahashi T, Hayashi H, Okada M, Inokawa H, Yoshioka H, Takahashi K, Higashiyama M, Yoshino I, Nakagawa K, West Japan Oncology Group.
    J Clin Oncol; 2022 Jan 20; 40(3):231-241. PubMed ID: 34726958
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, Jassem J, Yoshimura M, Dahabreh J, Nakayama H, Havel L, Kondo H, Mitsudomi T, Zarogoulidis K, Gladkov OA, Udud K, Tada H, Hoffman H, Bugge A, Taylor P, Gonzalez EE, Liao ML, He J, Pujol JL, Louahed J, Debois M, Brichard V, Debruyne C, Therasse P, Altorki N.
    Lancet Oncol; 2016 Jun 20; 17(6):822-835. PubMed ID: 27132212
    [Abstract] [Full Text] [Related]

  • 16. A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective.
    Barlesi F, Chouaid C, Crequit J, Le Caer H, Pujol JL, Legodec J, Vergnenegre A, Le Treut J, Fabre-Guillevin E, Loundou A, Auquier P, Simeoni MC, Thomas PA.
    Interact Cardiovasc Thorac Surg; 2015 Jun 20; 20(6):783-90. PubMed ID: 25765952
    [Abstract] [Full Text] [Related]

  • 17. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group.
    Keller SM, Adak S, Wagner H, Herskovic A, Komaki R, Brooks BJ, Perry MC, Livingston RB, Johnson DH.
    N Engl J Med; 2000 Oct 26; 343(17):1217-22. PubMed ID: 11071672
    [Abstract] [Full Text] [Related]

  • 18. Oral fluorouracil vs vinorelbine plus cisplatin as adjuvant chemotherapy for stage II-IIIA non-small cell lung cancer: Propensity score-matched and instrumental variable analyses.
    Urushiyama H, Jo T, Yasunaga H, Michihata N, Matsui H, Hasegawa W, Takeshima H, Sakamoto Y, Hiraishi Y, Mitani A, Fushimi K, Nagase T, Yamauchi Y.
    Cancer Med; 2018 Oct 26; 7(10):4863-4869. PubMed ID: 30151905
    [Abstract] [Full Text] [Related]

  • 19. Neo-adjuvant chemo/immunotherapy in the treatment of stage III (N2) non-small cell lung cancer: a phase I/II pilot study.
    Ratto GB, Costa R, Maineri P, Alloisio A, Piras MT, D'Agostino A, Tripodi G, Rivabella L, Dozin B, Bruzzi P, Melioli G.
    Int J Immunopathol Pharmacol; 2011 Oct 26; 24(4):1005-16. PubMed ID: 22230406
    [Abstract] [Full Text] [Related]

  • 20. Induction chemotherapy with cetuximab, vinorelbine-cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine-cisplatin in patients with unresectable stage III non-small cell lung cancer.
    Liu D, Zheng X, Chen J, Liu G, Xu Y, Shen Y, Xie L, Zhao W, Jiang G, Fan M.
    Lung Cancer; 2015 Sep 26; 89(3):249-54. PubMed ID: 26118463
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.